Total Payments
$849,501
2024 Payments
$56,276
Companies
47
Transactions
413
Medicare Patients
187
Medicare Billing
$30,269
Payment Breakdown by Category
Consulting$637,943 (75.1%)
Travel$134,702 (15.9%)
Other$65,258 (7.7%)
Food & Beverage$9,431 (1.1%)
Research$2,136 (0.3%)
Education$30.55 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $637,943 | 126 | 75.1% |
| Travel and Lodging | $134,702 | 119 | 15.9% |
| Honoraria | $35,740 | 9 | 4.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $29,518 | 5 | 3.5% |
| Food and Beverage | $9,431 | 147 | 1.1% |
| Unspecified | $2,136 | 6 | 0.3% |
| Education | $30.55 | 1 | 0.0% |
Payments by Type
General
$847,365
407 transactions
Research
$2,136
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk AS | $204,218 | 52 | $0 (2024) |
| INTERCEPT PHARMACEUTICALS, INC. | $178,734 | 39 | $0 (2023) |
| Novo Nordisk Inc | $89,499 | 32 | $0 (2024) |
| Theratechnologies Inc. | $68,181 | 11 | $0 (2021) |
| Gilead Sciences, Inc. | $36,927 | 73 | $0 (2022) |
| Kowa Research Institute, Inc. | $36,742 | 20 | $0 (2024) |
| PFIZER INC. | $23,940 | 13 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $23,410 | 9 | $0 (2022) |
| BioMarin Pharmaceutical Inc. | $20,960 | 7 | $0 (2024) |
| Madrigal Pharmaceuticals | $16,496 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $56,276 | 49 | Madrigal Pharmaceuticals ($16,496) |
| 2023 | $153,169 | 42 | INTERCEPT PHARMACEUTICALS, INC. ($93,000) |
| 2022 | $64,699 | 32 | Novo Nordisk AS ($22,345) |
| 2021 | $107,121 | 29 | Theratechnologies Inc. ($50,400) |
| 2020 | $135,319 | 39 | Intercept Pharmaceuticals, Inc. ($67,342) |
| 2019 | $201,821 | 113 | Novo Nordisk AS ($64,227) |
| 2018 | $93,394 | 49 | Novo Nordisk AS ($57,944) |
| 2017 | $37,702 | 60 | Intercept Pharmaceuticals, Inc. ($9,996) |
All Payment Transactions
413 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/29/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $8,000.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/10/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $363.06 | General |
| 12/10/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $109.02 | General |
| 12/10/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $47.81 | General |
| 12/10/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $30.07 | General |
| 12/08/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $84.26 | General |
| Category: LIVER DISEASE | ||||||
| 12/05/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Honoraria | Cash or cash equivalent | $2,400.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/02/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| 11/22/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| 11/19/2024 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $5,812.50 | General |
| 11/19/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $325.71 | General |
| 11/19/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $165.00 | General |
| 11/18/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $135.00 | General |
| 11/17/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $3,320.00 | General |
| 11/17/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $135.52 | General |
| Category: LIVER DISEASE | ||||||
| 11/16/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $37.20 | General |
| Category: LIVER DISEASE | ||||||
| 11/14/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| 10/28/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,200.00 | General |
| Category: LIVER DISEASE | ||||||
| 10/28/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $465.00 | General |
| Category: LIVER DISEASE | ||||||
| 10/28/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $135.47 | General |
| Category: LIVER DISEASE | ||||||
| 10/04/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $38.62 | General |
| Category: LIVER DISEASE | ||||||
| 10/01/2024 | Kowa Research Institute, Inc. | — | Consulting Fee | Cash or cash equivalent | $8,700.00 | General |
| 10/01/2024 | Kowa Research Institute, Inc. | — | Travel and Lodging | Cash or cash equivalent | $1,381.68 | General |
| 09/18/2024 | Kowa Research Institute, Inc. | — | Travel and Lodging | In-kind items and services | $221.70 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | Eli Lilly and Company | $1,142 | 3 |
| PREVALENCE AND BURDEN OF NASH AND NAFLD | Novartis Pharmaceuticals Corporation | $873.00 | 1 |
| NN9535-4321 | Novo Nordisk AS | $121.01 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 23 | 23 | $20,653 | $2,856 |
| 2022 | 3 | 40 | 50 | $24,938 | $6,176 |
| 2021 | 4 | 58 | 90 | $39,744 | $9,438 |
| 2020 | 4 | 66 | 112 | $46,115 | $11,798 |
Total Patients
187
Total Services
275
Medicare Billing
$30,269
Procedure Codes
13
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 11 | 11 | $7,909 | $1,698 | 21.5% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 12 | 12 | $12,744 | $1,159 | 9.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 11 | 12 | $8,628 | $2,187 | 25.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 15 | 15 | $8,145 | $2,021 | 24.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 14 | 23 | $8,165 | $1,969 | 24.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 16 | 47 | $15,565 | $4,061 | 26.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 18 | 19 | $9,283 | $2,999 | 32.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 13 | 13 | $4,622 | $1,234 | 26.7% |
| 43235 | Diagnostic examination of esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 11 | 11 | $10,274 | $1,144 | 11.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 26 | 70 | $22,400 | $5,605 | 25.0% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 15 | 15 | $9,540 | $2,490 | 26.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 11 | 12 | $7,440 | $2,040 | 27.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 14 | 15 | $6,735 | $1,663 | 24.7% |
About Dr. Rohit Loomba, MD
Dr. Rohit Loomba, MD is a Internal Medicine healthcare provider based in La Jolla, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1578593521.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rohit Loomba, MD has received a total of $849,501 in payments from pharmaceutical and medical device companies, with $56,276 received in 2024. These payments were reported across 413 transactions from 47 companies. The most common payment nature is "Consulting Fee" ($637,943).
As a Medicare-enrolled provider, Loomba has provided services to 187 Medicare beneficiaries, totaling 275 services with total Medicare billing of $30,269. Data is available for 4 years (2020–2023), covering 13 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Internal Medicine
- Location La Jolla, CA
- Active Since 07/04/2006
- Last Updated 01/08/2020
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1578593521
Products in Payments
- Victoza (Drug) $30,981
- Saxenda (Drug) $30,329
- REZDIFFRA (Drug) $13,800
- OCALIVA (Drug) $5,083
- Repatha (Biological) $4,578
- OCA (Drug) $4,428
- EGRIFTA (Drug) $4,031
- Novoeight (Drug) $3,750
- RESMETIROM (Drug) $2,696
- OBETICHOLIC ACID (Drug) $2,500
- NO PRODUCT DISCUSSED (Drug) $2,124
- XIFAXAN (Drug) $2,069
- ADVIA Centaur XP Analyzer (Device) $1,585
- GLASSIA (Biological) $1,400
- MK-3655 (Biological) $587.45
- ADVIA Immunoassay Reagents/Test Kit/Clinical Utilization (Device) $362.73
- TAVNEOS (Drug) $271.37
- HEMOSPRAY (Device) $191.66
- KRYSTEXXA (Biological) $124.48
- DUPIXENT (Biological) $122.16
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in La Jolla
Dr. Pam Taub, Md, MD
Internal Medicine — Payments: $1.5M
Internal Medicine $1.5M
Dr. Hyong Kim, M.d, M.D
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Dr. John Rogers, M.d, M.D
Internal Medicine — Payments: $852,868
Internal Medicine $852,868
Dr. Fouad Moawad, M.d, M.D
Internal Medicine — Payments: $526,722
Internal Medicine $526,722
Dr. Brian Modena, M.d., Msc, M.D., MSC
Internal Medicine — Payments: $471,187
Internal Medicine $471,187
Dr. Lewis Rubin, M.d, M.D
Internal Medicine — Payments: $354,421
Internal Medicine $354,421